INSM | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 15%

Liquidity 75%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

2.43%

1 Month

-0.76%

3 Months

-26.53%

6 Months

3.29%

1 Year

93.27%

2 Year

438.75%

Key data

Stock price

$149.88

P/E Ratio

0.00

DAY RANGE

$146.73 - $150.27

EPS

-$6.42

52 WEEK RANGE

$60.40 - $212.75

52 WEEK CHANGE

$99.79

MARKET CAP

37.118 B

YIELD

N/A

SHARES OUTSTANDING

215.552 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-07-2025

BETA

1.87

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,339,016

AVERAGE 30 VOLUME

$2,435,263

Company detail

CEO: William H. Lewis
Region: US
Website: insmed.com
Employees: 740
IPO year: 2000

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1.

INSM - INSMED Inc